Table 2.
Prevalence of Baseline Electrocardiographic Abnormalities by Quartile of OGTT or HOMA Parameters
Quartile 1 [range] | Quartile 2 [range] | Quartile 3 [range] | Quartile 4 [range] | p value a | |
---|---|---|---|---|---|
OGTT-derived MISIb | [0.35–1.66] | [1.68–2.48] | [2.49–3.73] | [3.76–14.69] | |
LVH (%) | 4.0 | 1.7 | 2.3 | 1.1 | 0.12 |
Q (%) | 15.3 | 8.6 | 8.0 | 6.3 | 0.005 |
ST-T (%) | 16.5 | 18.3 | 18.2 | 20.0 | 0.42 |
OGTT-derived IGIb | [0.003–0.10] | [0.11–0.24] | [0.25–0.48] | [0.49–7.58] | |
LVH (%) | 2.8 | 1.2 | 4.0 | 1.1 | 0.66 |
Q (%) | 11.3 | 7.5 | 7.4 | 12.0 | 0.84 |
ST-T (%) | 22.0 | 21.3 | 13.1 | 16.0 | 0.04 |
HOMA-IR | [0.58–2.92] | [2.93–4.36] | [4.39–7.09] | [7.11–47.72] e | |
[0.51–2.84] | [2.85–4.27] | [4.28–6.73] | [6.75–47.72] f | ||
LVH (%) | |||||
OGTT Subsampleb | 0.6 | 3.4 | 1.1 | 4.5 | 0.06 |
Total Samplec | 1.0 | 2.3 | 2.3 | 5.4 | <0.001 |
Q (%) | |||||
OGTT Subsampleb | 6.7 | 7.3 | 10.1 | 13.6 | 0.018 |
Total Samplec | 6.4 | 4.8 | 7.6 | 10.1 | 0.007 |
ST-T (%) | |||||
OGTT Subsampleb | 15.7 | 20.3 | 18.5 | 17.5 | 0.78 |
Total Samplec | 17.4 | 17.3 | 19.5 | 21.2 | 0.08 |
HOMA-Bd | [14.53–66.46] | [66.58–106.24] | [106.40–175.59] | [175.84–6480.00] e | |
[14.53–61.41] | [61.57–100.15] | [100.22–167.53] | [168.00–3204.00] f | ||
LVH (%) | |||||
OGTT Subsample | 2.3 | 1.1 | 4.5 | 1.7 | 0.74 |
Total Sample | 3.3 | 1.7 | 3.1 | 2.9 | 0.96 |
Q (%) | |||||
OGTT Subsample | 7.9 | 9.6 | 9.0 | 11.3 | 0.32 |
Total Sample | 6.8 | 6.8 | 7.2 | 8.0 | 0.45 |
ST-T (%) | |||||
OGTT Subsample | 21.9 | 19.8 | 14.6 | 15.8 | 0.07 |
Total Sample | 19.8 | 18.1 | 19.7 | 17.8 | 0.59 |
Statistical significance was tested using nonparametric test for trend across ordered groups, an extension of the Wilcoxon rank-sum test.
OGTT Subsample n=710;
Total Sample n=1671
Participants on insulin therapy were excluded for analyses of HOMA-B leaving n=1334 for Total sample and n=554 for OGTT subsample
Quartile ranges for participants in OGTT subsample
Quartile ranges for participants in the total sample
Abbreviations: HOMA-IR=homeostatic model assessment of insulin resistance, HOMA-B=homeostatic model assessment of beta-cell function